ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,231.05
0.59%
Dow Jones
38,111.48
-0.86%
Gold vs US Dollar
2,338.63
-0.21%
Brent Oil
81.595
-0.43%
Bitcoin
68,558.69
0.29%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Hyloris Pharmaceuticals SA (HYL)

  7. Hyloris Pharmaceuticals SA (HYL) News

Hyloris Pharmaceuticals (HYL)

Hyloris Pharmaceuticals SA
Date:
Sort by:
 Showing the most relevant articles for your search:EU:HYL
DateTimeSourceHeadlineSymbolCompany
14/03/202406:00GlobeNewswire Inc.Hyloris Présente ses Résultats Annuels pour 2023 et ses PerspectivesEU:HYLHyloris Pharmaceuticals SA
14/03/202406:00GlobeNewswire Inc.Hyloris Reports Full Year Results for 2023 & Provides Business OutlookEU:HYLHyloris Pharmaceuticals SA
14/03/202405:59GlobeNewswire Inc.Communication at the request of the FSMA on the transactions with QliniqEU:HYLHyloris Pharmaceuticals SA
14/03/202405:59GlobeNewswire Inc.Communiqué à la requête de la FSMA sur les transactions avec QliniQEU:HYLHyloris Pharmaceuticals SA
08/03/202406:00GlobeNewswire Inc.Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024EU:HYLHyloris Pharmaceuticals SA
08/03/202406:00GlobeNewswire Inc.Hyloris to Report 2023 Full-Year Results on 14 March 2024EU:HYLHyloris Pharmaceuticals SA
08/03/202406:00GlobeNewswire Inc.Hyloris to Report 2023 Full-Year Results on 14 March 2024EU:HYLHyloris Pharmaceuticals SA
27/02/202417:00GlobeNewswire Inc.Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au CanadaEU:HYLHyloris Pharmaceuticals SA
27/02/202417:00GlobeNewswire Inc.Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In CanadaEU:HYLHyloris Pharmaceuticals SA
14/02/202417:00GlobeNewswire Inc.Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental ProceduresEU:HYLHyloris Pharmaceuticals SA
14/02/202417:00GlobeNewswire Inc.Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions DentairesEU:HYLHyloris Pharmaceuticals SA
30/01/202406:00GlobeNewswire Inc.Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)EU:HYLHyloris Pharmaceuticals SA
30/01/202406:00GlobeNewswire Inc.Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)EU:HYLHyloris Pharmaceuticals SA
18/01/202418:00GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)EU:HYLHyloris Pharmaceuticals SA
18/01/202418:00GlobeNewswire Inc.Hyloris Elargit son Portefeuille de Produits avec un Nouveau Produit Candidat pour le Lichen Scléreux Vulvaire (LSV)EU:HYLHyloris Pharmaceuticals SA
16/01/202418:30GlobeNewswire Inc.Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)EU:HYLHyloris Pharmaceuticals SA
16/01/202418:30GlobeNewswire Inc.La FDA Américaine Accorde la Qualification de Médicament Orphelin au PTX-252 pour le Traitement de la Leucémie Myéloïde Aiguë (LMA)EU:HYLHyloris Pharmaceuticals SA
16/01/202418:30GlobeNewswire Inc.Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)EU:HYLHyloris Pharmaceuticals SA
16/01/202416:30GlobeNewswire Inc.Pleco Therapeutics receives FDA Orphan Drug DesignationEU:HYLHyloris Pharmaceuticals SA
26/12/202317:00GlobeNewswire Inc.Hyloris Annonce des Résultats Cliniques Positifs pour son Produit Valacyclovir (HY-029) en suspension oraleEU:HYLHyloris Pharmaceuticals SA
21/12/202317:30GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth SyndromeEU:HYLHyloris Pharmaceuticals SA
21/12/202317:30GlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth SyndromeEU:HYLHyloris Pharmaceuticals SA
21/12/202317:30GlobeNewswire Inc.Hyloris élargit son Portefeuille avec un Nouveau Produit Candidat pour le Syndrome de la Bouche BrûlanteEU:HYLHyloris Pharmaceuticals SA
04/12/202306:00GlobeNewswire Inc.Hyloris announces US FDA approval for Podofilox GelEU:HYLHyloris Pharmaceuticals SA
04/12/202306:00GlobeNewswire Inc.Hyloris announces US FDA approval for Podofilox GelEU:HYLHyloris Pharmaceuticals SA
04/12/202306:00GlobeNewswire Inc.Hyloris annonce l'approbation du Gel Podofilox par la FDA américaineEU:HYLHyloris Pharmaceuticals SA
24/10/202306:00GlobeNewswire Inc.Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in CanadaEU:HYLHyloris Pharmaceuticals SA
24/10/202306:00GlobeNewswire Inc.Hyloris annonce un accord de licence pour l'Atomoxetine Oral Liquide au CanadaEU:HYLHyloris Pharmaceuticals SA
24/10/202306:00GlobeNewswire Inc.Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in CanadaEU:HYLHyloris Pharmaceuticals SA
06/09/202321:00GlobeNewswire Inc.Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business OutlookEU:HYLHyloris Pharmaceuticals SA
 Showing the most relevant articles for your search:EU:HYL

Your Recent History

TSXV
REK
Reko International Group Inc.
NYSE
AQN
Algonquin Power
NASDAQ
PMD
Psychemedics
LSE
TEET
Vaneck Eu Ew
NYSE
AFL
AFLAC
NYSE
GTS
Triple S Management
LSE
SUSS
Is �cp 0-3 Esg
NASDAQ
CALI
EU
ABVX
Abivax
NYSE
WAB
Wabtec
NYSE
CMI
Cummins
NASDAQ
STRS
Stratus Properties
TSX
HERO
Evolve E Gaming Index ETF
NYSE
JWB
John Wiley & Sons
COIN
OCISLYETH
Of Course I Still Love You
NASDAQ
NOIZ
Micronetics
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved